Modern and Collaborative Approaches to Dry Eye Disease Diagnosis, Treatment, and Management (CME Webcast)
Program Overview
The number of people with dry eye disease (DED) is increasing, likely due to the influence of acts of modern living, such as use of digital screens and working in indoor office environments. The increase in DED prevalence is not age specific; both young and old patients are sitting in the chairs of eye care practitioners with signs and symptoms of DED. These patients are often first seen by optometrists, who are at the front line of eye health and work collaboratively with ophthalmologists on more severe cases of DED. This collaboration extends into the surgical room. A successful comanaging partnership between the optometrist and the ophthalmologist ensures that patients achieve and maintain a healthy ocular surface throughout the entire surgical process. The desired results of this activity are to update clinicians on diagnostic and treatment strategies for the management of DED as well as collaborative strategies that can better educate patients on their role in the successful management of their DED.
This continuing medical education activity is provided by New York Eye and Ear Infirmary of Mount Sinai. This educational activity was developed and implemented in collaboration with MedEdicus LLC.
This continuing medical education activity is supported through an unrestricted educational grant from Novartis Pharmaceuticals Corporation.
Click HERE for a downloadable patient education brochure on dry eye disease.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
Upon completion of this activity, participants will be better able to:
- Recognize factors that influence the evolving prevalence of dry eye disease
- Select appropriate tests for diagnosing dry eye disease
- Describe the implications of inflammation in dry eye disease on treatment
- Select the most appropriate treatment regimen for individual patients with dry eye disease
- Incorporate education regularly into patient encounters
Faculty
Kendall E. Donaldson, MD, MS (Co-Chair) Professor of Clinical Ophthalmology Medical Director Bascom Palmer Eye Institute in Plantation Plantation, Florida | |
Walter O. Whitley, OD, MBA, FAAO (Co-Chair) Director, Optometric Services Virginia Eye Consultants Virginia Beach, Virginia |
CME Reviewer for New York Eye and Ear Infirmary of Mount Sinai
Priti Batta, MD
Clinical Assistant Professor
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosure Policy
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
Disclosures
Kendall E. Donaldson, MD, MS, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Bausch & Lomb Incorporated; Dompé US, Inc; Eyevance; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; Lumenis; Omeros Corporation; TissueTech, Inc; and Zeiss.
Walter O. Whitley, OD, MBA, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; Bruder Healthcare; Eyevance; Glaukos Corporation; Horizon Therapeutics plc; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; Notal Vision; Novartis Pharmaceuticals Corporation; Ocular Therapeutix, Inc; OCuSOFT Inc; Oyster Point Pharma, Inc; Quidel Corporation; Regener-Eyes; RVL Pharmaceuticals, Inc; ScienceBased Health; Sun Pharmaceutical Industries, Inc; Tarsus Pharmaceuticals, Inc; TearLab Corporation; and Thea Pharmaceuticals Limited; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Alcon; Bausch & Lomb Incorporated; Bio-Tissue; Eyevance; Novartis Pharmaceuticals Corporation; ScienceBased Health; and Sun Pharmaceutical Industries, Inc; and Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Leo Lens Technology, Inc.
New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure
Priti Batta, MD, has no relevant commercial relationships to disclose.
Editorial Support Disclosures
Melissa Carter, MS; Cynthia Tornallyay, RD, MBA, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
Disclosure Attestation
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
Accreditation Statement
The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.
AMA Credit Designation Statement
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Grantor Statement
This continuing medical education activity is supported through an unrestricted educational grant from Novartis Pharmaceuticals Corporation.
Off-Label Discussion
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
https://www.nyee.edu/education/cme
CME Provider Contact Information
For questions about this activity, contact Kim Sponza at 203-461-0222.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, or Novartis Pharmaceuticals Corporation.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 236
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Clicking Register indicates that you have reviewed the CME information for this activity.
Learning Method and Medium
This educational activity consists of a six (6)-question pretest, a webcast, and four (4) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the posttest, and complete the evaluation. To receive credit for this activity, please complete the post test and evaluation. This educational activity should take a maximum of 1.0 hour to complete.